Valiant Organics Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Demand collapse, not market share loss: Volumes fell ~50% in chlorination and prices corrected across all chemistries, driven by a halving of European agrochemical demand, not competitive displacement.
• PAP "gold rush" is over: Margins have normalized to levels seen 4–5 years ago as new capacity came online; the 700–800 tonne/month volume target stands, but payback on the ₹270 cr CAPEX is now unquantifiable.
• Gross margin held at ~35% QoQ: Volume growth from pharma intermediates and PAP, plus raw material stabilization, offset price erosion, but management warns that if Q3 is poorer than Q2, margins will be "impacted significantly."
• Pharma intermediates are the lone bright spot: The multipurpose plant generated its first revenues in Q2, with 4–5 products set and all 8–10 expected online from Q1 FY25.
• What to watch next quarter: Whether the Q3 demand decline management flagged materializes, the pace of OAP's journey from 99% to 99.5% purity, and the standalone revenue trajectory toward the lowered ~₹800 cr guide.

Demand Environment

• European agrochemicals in freefall: The Russia-Ukraine war has halved European demand projections for the year; agro fairs and BSF are down ~50%, and inventories remain in the system. Chlorination, Valiant's highest-margin chemistry, saw volumes drop 50% purely on absent demand.
• Domestic market hit indirectly: Half of chlorination sales are domestic, but those customers are themselves dependent on European end-markets, so the weakness transmits through.
• All chemistries down together: Unlike historical cycles where dyes and agro moved independently, the current macro environment has depressed every chemistry simultaneously.
• Dyes & pigments: a false dawn: Ammonolysis volumes rose in Q2, but the current quarter has already reversed that trend; the Q2 uptick was a one-time blip between peaks.
• Chinese distress adds supply-side pressure: Two to three Chinese competitors have shut down again, this time because market prices are too low to sustain operations, not environmental enforcement. Those that remain are distress-selling.

Shah: “No, in fact, it’s slightly poorer than the previous quarter.”

PAP: Normalization, Not Catastrophe

• Margins back to pre-boom levels: The "gold rush" period of elevated PAP margins is over as new capacity entered the market. Margins have reverted to what they were 4–5 years ago, not below.
• Volume target intact, economics uncertain: Management still aims for 700–800 tonnes per month by year-end, but at current margins the ₹270 cr CAPEX payback period is impossible to calculate; it depends entirely on when full utilization is achieved.
• Captive consumption provides a floor: Of 800–850 tonnes monthly production, 700–750 tonnes goes to Valiant Laboratories, insulating the unit from some market dynamics.
• Competitive parity with China: Valiant competes at the same price level as Chinese producers domestically, not lower; Chinese players have good manufacturing and are facing the same difficulties.

Shah: "It is difficult to figure out where our payback is going to be at this moment. And other problem is that, it will largely depend on when we achieve our full capacity utilization."

Pharma Intermediates & New Molecules

• Pharma plant generating revenue: The multipurpose plant with ~12 products saw its first revenues in Q2; 4–5 products are set, and all 8–10 should come online from Q1 FY25. Management described the revenue as a "good amount."
• New chlorophenol molecule margin-accretive: One new molecule has started production, with sizable volume expected in a couple of weeks; another is still in development. It will improve profitability without significantly moving the top line.
• OAP purity progressing: Yield has improved from 90–95% to 99% purity; the target is 99.5%. Management expects OAP to "ideally come online" by year-end at ~100 tonnes per month.

Competitive Position & Barriers

• Chlorination has structural protection: Demand is capped at 5,000–6,000 tonnes per month with no growth, making additional capacity unviable for any new entrant. Valiant can compete with China on cost "easily."
• PNA competitive but unprotected: No anti-dumping duty exists on Para Nitro Aniline; Valiant competes with three or four domestic players plus Chinese imports, all at equal pricing.
• Fire incident not a factor: Customers remain; the demand issue is entirely agro-molecule-specific, not a lingering effect of last year's fire.

Margins & Cost Structure

• Gross margin stable at ~35% QoQ: Volume growth from pharma intermediates and PAP, combined with raw material stabilization, offset price corrections.
• Most other expenses are fixed: Beyond power and steam, costs like insurance do not flex with volumes, so the operating leverage works negatively in a downturn.
• Pricing power absent: In a declining market with powerful buyers, margins are compromised to stay competitive despite quarterly contracts.
• Chlorination margin stress: Chlorination normally carries better margins than PAP, but at current low utilization the advantage has eroded; 75–80% utilization is needed for it to be more profitable.

Shah: “I will not be able to comment on this margin because it’s too uncertain. I don’t want to say a number and then not live up to it.”

Capital Allocation & Structure

• No further CAPEX: All plants are at 50% utilization; expansion would only deepen underutilization. Management wants to stabilize the three projects already undertaken over the last 3–4 years.
• Valiant Laboratories deconsolidation: Stake fell to 35% on 6th October; from next quarter, no line-by-line consolidation. Management has no plan to exit or monetize the stake.
• Buyback not imminent: Management left the door open for something "going forward" but ruled out the immediate future.

Shah: "Right now, all our plants are operating at 50% capacity, by expansion we are only going to be underutilized even further."

Guidance & Commitments

Key Metrics